孟鲁司特治疗重度慢性阻塞性肺疾病急性加重对免疫功能影响的分析  

Clinical analysis of acute exacerbation of chronic obstructive pulmonary disease treated with montelukast on immune function

作　　者：张文强[1] 苏筠霞[1] 巩增锋[1] 李亚彬[1] 张彦军[1] 魏萍[1] 

机构地区：[1]兰州大学第一医院东岗院区呼吸科,甘肃兰州730020

出　　处：《兰州大学学报（医学版）》2013年第3期25-27,共3页Journal of Lanzhou University（Medical Sciences）

摘　　要：目的探讨孟鲁司特联合舒利迭治疗重度慢性阻塞性肺疾病(COPD)急性加重对免疫功能的影响。方法将113例重度COPD急性加重期患者,随机分为孟鲁司特联合舒利迭治疗组57例,单纯舒利迭治疗组56例,治疗14 d后,评价所有患者治疗前、后T细胞亚群CD_3^+、CD_4^+及CD_4^+/CD_8^+的变化。结果治疗组CD_3^+、CD_4^+、CD_4^+/CD_8^+指标差异有统计学意义(P<0.05),而对照组无明显变化,药物冶疗安全性好。结论孟鲁司特钠联合舒利迭治疗中重度COPD急性加重期,能有效改善患者免疫功能,提高患者免疫力。Objective To observe the influence of montelukast sodium combined with seretide in treatment of severe acute exacerbation of chronic obstructive pulmonary disease（COPD） on immune function.Methods 113 patients with severe COPD,were randomly devided into 57 cases of montelukast combined with seretide treatment group,56 cases of simple treatment group.After14 d treatment,evaluation of changes was made in all patients before and after treatment of T cell subsets（CD₃⁺,CD⁺ and CD₄⁺/CD₈⁺）.Results The above indexes for treatment group had statistic differences（P&lt;0.05）,while no significant changes in control group with good drug safety.Conclusion Montelukast combined with seretide can effectively improve immune functions of the patients in the treatment of severe COPD.

关 键 词：孟鲁司特 慢性阻塞性肺疾病 免疫功能 

分 类 号：R[医药卫生]